Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RAD51C R168G |
Therapy | Olaparib |
Indication/Tumor Type | osteosarcoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51C R168G | osteosarcoma | sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, the expression of RAD51C R168G sensitized RAD51C-null osteosarcoma cells to Lynparza (olaparib) treatment in culture, resulting in decreased cell survival (PMID: 37253112). | 37253112 |
PubMed Id | Reference Title | Details |
---|---|---|
(37253112) | Functional and clinical characterization of variants of uncertain significance identifies a hotspot for inactivating missense variants in RAD51C. | Full reference... |